7.31
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
24.94%
13.47
|
10.79 | 13.25 | 14.54 | 13.46 |
| Cost Of Revenue |
51.32%
2.011
|
1.329 | 1.594 | 1.774 | 1.944 |
| Research and Development |
18.24%
54.14
|
66.21 | - | - | - |
| Costs And Expenses |
8.20%
95.58
|
104.12 | 83.01 | 83.24 | 81.10 |
| Operating Income/Loss |
12.03%
-82.11
|
-93.34 | -69.76 | -68.70 | -67.64 |
| Nonoperating Income/Loss |
29.23%
3.346
|
4.728 | 5.106 | -0.72 | -0.173 |
| Net Income/Loss |
11.11%
-78.76
|
-88.61 | -64.65 | -69.42 | -67.81 |
| Basic Average Shares |
0.38%
224.95
|
224.10 | 11.88 | 183.92 | 172.59 |
| Diluted Average Shares |
0.38%
224.95
|
224.10 | 11.88 | 183.92 | 172.59 |
| Basic Earnings Per Share |
12.50%
-0.35
|
-0.40 | -0.27 | -0.38 | -0.39 |
| Diluted Earnings Per Share |
12.50%
-0.35
|
-0.40 | -0.27 | -0.38 | -0.39 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):